Thymosin Alpha-1

1.6 mg

under the skin · once per day · for 5 days

Efficacy of Thymosin alpha1 for Severe SepsisNA · NCT00711620

“1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days..”

See source wording

Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant MelanomaPHASE2 · NCT00911443

“Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg.”

See source wording

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 VaccinePHASE1 · NCT06821100

“A 4.8 mg dose of Ta1 (dose of 1.6 mg in 1 mL of diluent X3) on Day 0, followed by vaccination.”

1.6 mg

under the skin · for 3 months

Immuno-effect of Tα1 for Stage I NSCLCNA · NCT06598839

“subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months.”

See source wording

A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza VaccinePHASE2 · NCT01031966

“1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0).”

See source wording

under the skin · twice a week · for 24 weeks

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced PatientsPHASE4 · NCT03448744

“Thymosin Alpha1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks.”

1.6 mg

under the skin · twice a week · for 1 month

Thymosin Alpha-1 for irAE Secondary to ICIsPHASE4 · NCT06178146

“Based on the conventional treatment, subcutaneous injection of Tα-1 (1.6 mg, qd) in Week 1; and in Week 2, subcutaneous injection of thymalfasin 1.6 mg, 3 times a week, followed by twice a week for 1 month since Week 3..”

See source wording

under the skin · weekly

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLCPHASE2 · NCT06139419

“All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1..”

1.6 mg

under the skin

The Efficacy and Safety of Ta1 for SepsisPHASE3 · NCT02867267

“Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent..”

See source wording

every 12 hours · for 5 days

Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)NA · NCT05339529

“Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-.”

See source wording

three times per week

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaPHASE2 · NCT07644897

“Thymosin Alpha 1 1.6mg, sc，QD，d1-7;1.6mg, sc，three times per week, d8-21 Anti-PD-1 monoclonal antibody (Toripalimab) 240mg per dose,ivdrip，Q3W.”

1.6 mg

every 12 hours · for 5 days

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary BypassNA · NCT05487469

“Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission.”

1.6 mg

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing PancreatitisPHASE4 · NCT02473406

“In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge..”

See source wording

under the skin

SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyPHASE2 · NCT02976740

“Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle.”

1.6 mg

under the skin · weekly

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis BPHASE4 · NCT00291616

“injection weekly Thymosin 1.6 mg s.c.”

1.6 mg

under the skin · twice per day

Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for SepsisPHASE4 · NCT02883595

“Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent..”

1.6 mg

under the skin · weekly · for 8 weeks

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis PatientsPHASE2 · NCT04428008

“1.6 mg thymalfasin in 1 mL subcutaneous injection twice weekly after dialysis for 8 weeks.”

See source wording

for 1 year

TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell CarcinomaNA · NCT06401447

“Chemotherapy: paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.”

See source wording

for 15 weeks

REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infectionPHASE2 · NCT02233075

“15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC).”

See source wording

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI TherapyPHASE2 · NCT02787447

“Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid.”

1.6 mg

daily

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 InfectionPHASE2 · NCT04487444

“Ta1 at a dose of 1.6 mg will be administered SC in 1 mL of diluent daily for a total of 1 week, in addition to standard of care..”

1.6 mg

under the skin · twice a week · for 6 months

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal CancerPHASE3 · NCT05086614

“Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection..”

1.6 mg

for 5 days

Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)NA · NCT06966687

“Ulinastatin (100000U TID for 5 days) and Thymosin alpha 1 (1.6 mg q12h for 5 days) immediately after surgery.”

1.6 mg

once a day · for 16 weeks

Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological MalignanciesPHASE1, PHASE2 · NCT00580450

“1.6 mg sc once a day for 16 weeks.”

0.6 mg/kg

mice · another route · for 5 days

Thymosin alpha 1 as an adjuvant to hyperthermic intraperitoneal chemotherapy in an experimental model of peritoneal metastases from colonic carcinoma.International immunopharmacology · 2022

“Mice were treated with Tα1 at 0.6 mg/kg for 5 days after HIPEC.”